Ultimovacs was founded in 2011 and is a limited company listed on the Oslo Stock Exchange in Norway. The company and its patented technology are based on preclinical and clinical research on immunotherapies conducted at Oslo University Hospital.
Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden as a result of an acquisition of the cancer virus project that, among others, Uppsala University Invest co-financed.
